<DOC>
	<DOCNO>NCT00408278</DOCNO>
	<brief_summary>Primary objective - To evaluate efficacy toxicity risk-adapted protocol use idarubicin induction consolidation therapy patient APL . - To evaluate impact mitoxantrone reduction event-free , disease-free , overall survival , well duration remission cumulative incidence relapse low- intermediate-risk patient APL . - To evaluate impact addition ara-C idarubicin course consolidation high-risk patient ( administer original GIMEMA protocol ) event-free , disease-free , overall survival , well duration remission cumulative incidence relapse . - To evaluate toxicity induction , consolidation , maintenance chemotherapy whole series treatment group patient APL . Secondary objective • To compare outcomes achieve PETHEMA LPA99 protocol .</brief_summary>
	<brief_title>Treatment Newly Diagnosed Patients With Acute Promyelocytic Leukemia ( PETHEMA LPA 2005 )</brief_title>
	<detailed_description>Treatment induction simultaneous administration ATRA ( 45 mg/m2 day RC ) idarubicine ( 12 mg/m2 day 2 , 4 , 6 8 ) , 3 monthly cycle consolidation ATRA ( 45 mg/m2 day 1-15 ) idarubicine ( 5 mg/m2 day 1-4 ) cycle # 1 , mitoxantrone ( 10 mg/m2 day 1-3 ) cycle # 2 idarubicine ( 12 mg/m2 day 1 ) cycle # 3 . The consolidation reinforce group patient intermediate risk mean increase idarubicine 7 mg cycle # 1 2 day cycle # 3 . In patient high risk , consolidation reinforce addition altar-c cycle # 1 # 3 . For maintenance treatment , one administer intermittent ATRA ( 15 day every 3 month ) chemotherapy low dos methotrexate 6-mercaptopurina two year</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Age ≤ 75 year . ECOG ≤ 3 . Morphologic Diagnosis LPA ( FAB M3 variant M3 ) . Those case without typical morphology PMLRARα reordering also must include . Genetic Diagnosis : ( 15 ; 17 ) demonstrate cariotipo conventional , FISH , PMLRARα reorder detect RTPCR pattern microspeckled demonstrate antibody antiPML ( positive PGM3 ) . Obvious , result test initiate treatment basis suspicion diagnose morphologic Age &gt; 75 year ( treatment protocol consider individually ) Absence PMLRare reorder . To receive previously type treatment LPA , include chemotherapy retinoides . The previous treatment corticoid , hidroxiurea leucoaféresis reason exclusion . To receive chemotherapy xray treatment disease vitiate previous . Associate Neoplasia . Serious psychiatric Disease . Seropositividad VIH . Contraindication receive intensive chemotherapy , specially antraciclinas . Sérica Creatinina ≥ 2,5 mg/dL ( ≥ 250 μmol/l ) . Bilirrubina , fosfatasa alkaline , GOT &gt; 3 time normal limit Test positive pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Acute Promyelocytic Leukemia</keyword>
</DOC>